

Bruce A Mueller

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3261639/publications.pdf>

Version: 2024-02-01

112
papers

4,345
citations

117571

34
h-index

123376

61
g-index

117
all docs

117
docs citations

117
times ranked

3192
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Evaluation and Development of Vancomycin Dosing Schemes to Meet New AUC/MIC Targets in Intermittent Hemodialysis Using Monte Carlo Simulation Techniques. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 211-223. | 1.0 | 9 |
| 2 | Telavancin pharmacokinetics in patients with chronic kidney disease receiving haemodialysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 77, 174-180. | 1.3 | 0 |
| 3 | Imipenem/Relebactam Ex Vivo Clearance during Continuous Renal Replacement Therapy. <i>Antibiotics</i> , 2021, 10, 1184. | 1.5 | 2 |
| 4 | Size Matters: The Influence of Patient Size on Antibiotics Exposure Profiles in Critically Ill Patients on Continuous Renal Replacement Therapy. <i>Antibiotics</i> , 2021, 10, 1390. | 1.5 | 3 |
| 5 | Therapeutic Monitoring of Vancomycin for Serious Methicillin-resistant <i>Staphylococcus aureus</i> Infections: A Revised Consensus Guideline and Review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. <i>Clinical Infectious Diseases</i> , 2020, 71, 1361-1364. | 2.9 | 142 |
| 6 | Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant <i>Staphylococcus aureus</i> Infections: A Revised Consensus Guideline and Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2020, 9, 281-284. | 0.6 | 33 |
| 7 | Questions on Vancomycin Dosing. <i>Clinical Infectious Diseases</i> , 2020, 73, e1777-e1778. | 2.9 | 1 |
| 8 | Harmonizing antibiotic regimens with renal replacement therapy. <i>Expert Review of Anti-Infective Therapy</i> , 2020, 18, 887-895. | 2.0 | 5 |
| 9 | Therapeutic monitoring of vancomycin for serious methicillin-resistant <i>Staphylococcus aureus</i> infections: A revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. <i>American Journal of</i> | 0.5 | 640 |
| 10 | Executive Summary: Therapeutic Monitoring of Vancomycin for Serious Methicillin-Resistant <i>Staphylococcus aureus</i> Infections: A Revised Consensus Guideline and Review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. <i>Pharmacotherapy</i> , 2020, 40, 363-367. | 1.2 | 56 |
| 11 | Single dose oral ranolazine pharmacokinetics in patients receiving maintenance hemodialysis. <i>Renal Failure</i> , 2019, 41, 118-125. | 0.8 | 3 |
| 12 | Impact of hemodialysis on the concentrations of sodium and potassium during infusion of sodium thiosulfate using an In Vitro hemodialysis model. <i>PLoS ONE</i> , 2019, 14, e0224767. | 1.1 | 1 |
| 13 | Antibiotic Exposure Profiles in Trials Comparing Intensity of Continuous Renal Replacement Therapy. <i>Critical Care Medicine</i> , 2019, 47, e863-e871. | 0.4 | 16 |
| 14 | Renal Dosing of Antibiotics: Are We Jumping the Gun?. <i>Clinical Infectious Diseases</i> , 2019, 68, 1596-1602. | 2.9 | 85 |
| 15 | Prevention of hypophosphatemia during continuous renal replacement therapy—An overlooked problem. <i>Seminars in Dialysis</i> , 2018, 31, 213-218. | 0.7 | 17 |
| 16 | Influence of hemodialysis on regadenoson clearance in an in vitro hemodialysis model. <i>Journal of Nuclear Cardiology</i> , 2018, 25, 234-239. | 1.4 | 5 |
| 17 | Acetaminophen clearance during ex vivo continuous renal replacement therapies. <i>Journal of Artificial Organs</i> , 2018, 21, 215-219. | 0.4 | 3 |
| 18 | Development of a vancomycin dosing approach for critically ill patients receiving hybrid hemodialysis using Monte Carlo simulation. <i>SAGE Open Medicine</i> , 2018, 6, 205031211877325. | 0.7 | 16 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Preparation times and costs for various solutions used for continuous renal replacement therapy. <i>American Journal of Health-System Pharmacy</i> , 2018, 75, 808-815. | 0.5 | 5 |
| 20 | A Monte Carlo Simulation Approach for Beta-lactam Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 1254-1265. | 1.0 | 20 |
| 21 | Ex vivo Rezapungin Adsorption and Clearance During Continuous Renal Replacement Therapy. <i>Blood Purification</i> , 2018, 46, 214-219. | 0.9 | 15 |
| 22 | Ex vivo Ceftolozane/Tazobactam Clearance during Continuous Renal Replacement Therapy. <i>Blood Purification</i> , 2017, 44, 16-23. | 0.9 | 25 |
| 23 | Antibiotic Dosing in Continuous Renal Replacement Therapy. <i>Advances in Chronic Kidney Disease</i> , 2017, 24, 219-227. | 0.6 | 24 |
| 24 | Antibiotic Dosing in Patients With Acute Kidney Injury. <i>Journal of Intensive Care Medicine</i> , 2016, 31, 164-176. | 1.3 | 56 |
| 25 | Ceftolozane/Tazobactam Clearance During In Vitro Continuous Renal Replacement Therapy (CRRT). <i>Open Forum Infectious Diseases</i> , 2016, 3, . | 0.4 | 0 |
| 26 | Contemporary Vancomycin Dosing in Chronic Hemodialysis (HD) Patients Does Not Meet AUC Targets: Development of a New Dosing Model Using Monte Carlo Simulation (MCS). <i>Open Forum Infectious Diseases</i> , 2016, 3, . | 0.4 | 1 |
| 27 | Antimicrobial Doses in Continuous Renal Replacement Therapy: A Comparison of Dosing Strategies. <i>Critical Care Research and Practice</i> , 2016, 2016, 1-6. | 0.4 | 6 |
| 28 | Dose Timing of Aminoglycosides in Hemodialysis Patients: A Pharmacology View. <i>Seminars in Dialysis</i> , 2016, 29, 204-213. | 0.7 | 10 |
| 29 | “In Through the Out Door”. <i>Pediatric Critical Care Medicine</i> , 2016, 17, 373-374. | 0.2 | 0 |
| 30 | Use of Monte Carlo Simulations to Determine Optimal Carbapenem Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 1277-1287. | 1.0 | 33 |
| 31 | We Underdose Antibiotics in Patients on CRRT. <i>Seminars in Dialysis</i> , 2016, 29, 278-280. | 0.7 | 34 |
| 32 | In silico trials using Monte Carlo simulation to evaluate ciprofloxacin and levofloxacin dosing in critically ill patients receiving prolonged intermittent renal replacement therapy. <i>Renal Replacement Therapy</i> , 2016, 2, . | 0.3 | 11 |
| 33 | Association of Oseltamivir Activation with Gender and Carboxylesterase 1 Genetic Polymorphisms. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2016, 119, 555-561. | 1.2 | 33 |
| 34 | Survey of pharmacists’ antibiotic dosing recommendations for sustained low-efficiency dialysis. <i>International Journal of Clinical Pharmacy</i> , 2016, 38, 127-134. | 1.0 | 16 |
| 35 | Fluconazole dosing predictions in critically-ill patients receiving prolonged intermittent renal replacement therapy: a Monte Carlo simulation approach. <i>Clinical Nephrology</i> , 2016, 86, 43-50. | 0.4 | 16 |
| 36 | Tedizolid Adsorption and Transmembrane Clearance during in vitro Continuous Renal Replacement Therapy. <i>Blood Purification</i> , 2015, 40, 66-71. | 0.9 | 19 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | How can we ensure effective antibiotic dosing in critically ill patients receiving different types of renal replacement therapy?. <i>Diagnostic Microbiology and Infectious Disease</i> , 2015, 82, 92-103. | 0.8 | 68 |
| 38 | Pharmacokinetics of Ertapenem in Critically Ill Patients Receiving Continuous Venovenous Hemodialysis or Hemodiafiltration. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1320-1326. | 1.4 | 32 |
| 39 | Antibiotic Dosing in Critically Ill Patients Receiving <scp>CRRT</scp>: Underdosing is Overprevalent. <i>Seminars in Dialysis</i> , 2014, 27, 441-445. | 0.7 | 47 |
| 40 | Principles and Operational Parameters to Optimize Poison Removal with Extracorporeal Treatments. <i>Seminars in Dialysis</i> , 2014, 27, 371-380. | 0.7 | 46 |
| 41 | Medication Dosing in Critically Ill Patients With Acute Kidney Injury Treated With Renal Replacement Therapy. <i>American Journal of Kidney Diseases</i> , 2013, 61, 490-500. | 2.1 | 35 |
| 42 | Intradialytic Oral Nutritional Supplements Improve Quality of Life. <i>American Journal of Kidney Diseases</i> , 2013, 61, 349. | 2.1 | 10 |
| 43 | Reenvisioning Assessment for the Academy and the Accreditation Council for Pharmacy Education's Standards Revision Process. <i>American Journal of Pharmaceutical Education</i> , 2013, 77, 141. | 0.7 | 7 |
| 44 | Vibration Enhances Clearance of Solutes With Varying Molecular Weights During In Vitro Hemodialysis. <i>ASAIO Journal</i> , 2013, 59, 140-144. | 0.9 | 1 |
| 45 | Daptomycin Pharmacokinetics and Pharmacodynamics in a Pooled Sample of Patients Receiving Thrice-Weekly Hemodialysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 864-872. | 1.4 | 21 |
| 46 | Ethambutol Optic Neuropathy in a Hemodialysis Patient Receiving a Guideline-Recommended Dose. <i>Journal of Neuro-Ophthalmology</i> , 2013, 33, 421-423. | 0.4 | 5 |
| 47 | <i>In Vitro</i> Glucose Kinetics during Continuous Renal Replacement Therapy: Implications for Caloric Balance in Critically Ill Patients. <i>International Journal of Artificial Organs</i> , 2013, 36, 861-868. | 0.7 | 17 |
| 48 | Adding to the Armamentarium. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 373-375. | 2.2 | 16 |
| 49 | Pharmacokinetics of Oseltamivir and Oseltamivir Carboxylate in Critically <scp>I</scp> Patients Receiving Continuous Venovenous Hemodialysis and/or Extracorporeal Membrane Oxygenation. <i>Pharmacotherapy</i> , 2012, 32, 1061-1069. | 1.2 | 37 |
| 50 | The Pharmacokinetics of Oseltamivir and Oseltamivir Carboxylate in a Critically Ill Pediatric Patient Receiving Extracorporeal Membrane Oxygenation and Continuous Venovenous Hemodialysis. <i>Journal of Pediatric Pharmacology and Therapeutics</i> , 2012, 17, 173-176. | 0.3 | 13 |
| 51 | Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis. <i>Critical Care Medicine</i> , 2011, 39, 19-25. | 0.4 | 89 |
| 52 | Daptomycin pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy. <i>Critical Care Medicine</i> , 2011, 39, 1244-1245. | 0.4 | 2 |
| 53 | Carbamazepine and the active epoxide metabolite are effectively cleared by hemodialysis followed by continuous venovenous hemodialysis in an acute overdose. <i>Hemodialysis International</i> , 2011, 15, 412-415. | 0.4 | 24 |
| 54 | Safety of Daptomycin in Patients Receiving Hemodialysis. <i>Pharmacotherapy</i> , 2011, 31, 665-672. | 1.2 | 13 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Antibiotic dosing in critically ill patients with acute kidney injury. <i>Nature Reviews Nephrology</i> , 2011, 7, 226-235. | 4.1 | 85 |
| 56 | Longitudinal Hemodiafilter Performance in Modeled Continuous Renal Replacement Therapy. <i>Blood Purification</i> , 2011, 32, 82-88. | 0.9 | 23 |
| 57 | Modeled Dalbavancin Transmembrane Clearance during Intermittent and Continuous Renal Replacement Therapies. <i>Blood Purification</i> , 2010, 30, 37-43. | 0.9 | 23 |
| 58 | Single-dose daptomycin pharmacokinetics in chronic haemodialysis patients. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 1279-1284. | 0.4 | 44 |
| 59 | Antibiotic Pharmacokinetic and Pharmacodynamic Considerations in Patients With Kidney Disease. <i>Advances in Chronic Kidney Disease</i> , 2010, 17, 392-403. | 0.6 | 30 |
| 60 | Drug Dosing in Acute Kidney Injury and During Renal Replacement Therapy. , 2010, , 241-251. | | 0 |
| 61 | Telavancin and Hydroxy Propyl- β -Cyclodextrin Clearance during Continuous Renal Replacement Therapy: An <i>in vitro</i> Study. <i>International Journal of Artificial Organs</i> , 2009, 32, 745-751. | 0.7 | 17 |
| 62 | Therapeutic Controversies: Optimizing Anemia Management in Hospitalized Patients with End-Stage Renal Disease. <i>Annals of Pharmacotherapy</i> , 2009, 43, 276-282. | 0.9 | 8 |
| 63 | Etanercept Clearance during an <i>in vitro</i> Model of Continuous Venovenous Hemofiltration. <i>Blood Purification</i> , 2009, 28, 348-353. | 0.9 | 2 |
| 64 | Pharmacist leads primary care team to improve diabetes care. <i>American Journal of Health-System Pharmacy</i> , 2009, 66, 622-624. | 0.5 | 6 |
| 65 | Intradialytic Administration of Daptomycin in End Stage Renal Disease Patients on Hemodialysis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009, 4, 1190-1194. | 2.2 | 40 |
| 66 | Continuous venovenous hemodiafiltration trace element clearance in pediatric patients: a case series. <i>Pediatric Nephrology</i> , 2009, 24, 807-813. | 0.9 | 27 |
| 67 | THE CLINICAL APPLICATION OF CRRTâ€™CURRENT STATUS: Drug Dosing During Continuous Renal Replacement Therapy. <i>Seminars in Dialysis</i> , 2009, 22, 185-188. | 0.7 | 54 |
| 68 | Effects of Peridialytic Oral Supplements on Nutritional Status and Quality of Life in Chronic Hemodialysis Patients. , 2009, 19, 145-152. | | 43 |
| 69 | Drug Dosing in Patients with Acute Kidney Injury and in Patients Undergoing Renal Replacement Therapy. , 2009, , 1727-1730. | | 0 |
| 70 | Amino Acid Requirements in Critically Ill Patients with Acute Kidney Injury Treated with Continuous Renal Replacement Therapy. <i>Pharmacotherapy</i> , 2008, 28, 600-613. | 1.2 | 65 |
| 71 | Clinical review: Drug metabolism and nonrenal clearance in acute kidney injury. <i>Critical Care</i> , 2008, 12, 235. | 2.5 | 83 |
| 72 | Enhanced clearance of highly protein-bound drugs by albumin-supplemented dialysate during modeled continuous hemodialysis. <i>Nephrology Dialysis Transplantation</i> , 2008, 24, 231-238. | 0.4 | 47 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Influence of Hemodialysis on Gentamicin Pharmacokinetics, Removal During Hemodialysis, and Recommended Dosing. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2008, 3, 355-361. | 2.2 | 58 |
| 74 | Trace element removal during in vitro and in vivo continuous haemodialysis. <i>Nephrology Dialysis Transplantation</i> , 2007, 22, 2970-2977. | 0.4 | 45 |
| 75 | Transplacental Passage of Vancomycin in Noninfected Term Pregnant Women. <i>Obstetrics and Gynecology</i> , 2007, 109, 1105-1110. | 1.2 | 30 |
| 76 | Selected Pharmacokinetic Issues in Patients with Chronic Kidney Disease. <i>Blood Purification</i> , 2007, 25, 133-138. | 0.9 | 9 |
| 77 | Drug Dosing Considerations in Alternative Hemodialysis. <i>Advances in Chronic Kidney Disease</i> , 2007, 14, e17-e26. | 0.6 | 21 |
| 78 | Outcomes of an Erythropoietic Growth Factor Interchange Program in Hospitalized Chronic Hemodialysis Patients. <i>Hospital Pharmacy</i> , 2007, 42, 119-125. | 0.4 | 2 |
| 79 | Drug-Associated Renal Dysfunction. <i>Critical Care Clinics</i> , 2006, 22, 357-374. | 1.0 | 119 |
| 80 | Daptomycin Clearance during Modeled Continuous Renal Replacement Therapy. <i>Blood Purification</i> , 2006, 24, 548-554. | 0.9 | 78 |
| 81 | Subcutaneous Terbutaline Use in CKD to Reduce Potassium Concentrations. <i>American Journal of Kidney Diseases</i> , 2005, 45, 1040-1045. | 2.1 | 26 |
| 82 | Pharmacokinetics of Intravenously Administered Levofloxacin in Men and Women. <i>Pharmacotherapy</i> , 2005, 25, 1310-1318. | 1.2 | 10 |
| 83 | In vitro clearance of trace elements via continuous renal replacement therapy. , 2004, 14, 214-219. | | 11 |
| 84 | In vitro clearance of trace elements via continuous renal replacement therapy. , 2004, 14, 214-219. | | 36 |
| 85 | In vitro clearance of trace elements via continuous renal replacement therapy. <i>Journal of Renal Nutrition</i> , 2004, 14, 214-9. | 0.1 | 10 |
| 86 | Pre dialysis of blood prime in continuous hemodialysis normalizes pH and electrolytes. <i>Pediatric Nephrology</i> , 2003, 18, 1177-1183. | 0.9 | 54 |
| 87 | Effects of sevelamer hydrochloride and calcium acetate on the oral bioavailability of ciprofloxacin. <i>American Journal of Kidney Diseases</i> , 2003, 42, 1253-1259. | 2.1 | 73 |
| 88 | Ofloxacin clearance during continuous hemofiltration. <i>American Journal of Kidney Diseases</i> , 2003, 42, 1326-1327. | 2.1 | 1 |
| 89 | Levofloxacin pharmacokinetics in ESRD and removal by the cellulose acetate high performance-210 hemodialyzer. <i>American Journal of Kidney Diseases</i> , 2003, 42, 342-349. | 2.1 | 19 |
| 90 | Linezolid Clearance During Continuous Venovenous Hemodiafiltration: A Case Report. <i>Pharmacotherapy</i> , 2003, 23, 1071-1075. | 1.2 | 28 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Higher Renal Replacement Therapy Dose Delivery Influences on Drug Therapy. <i>Artificial Organs</i> , 2003, 27, 808-814. | 1.0 | 70 |
| 92 | CAHP-210 dialyzer influence on intra-dialytic vancomycin removal. <i>Nephrology Dialysis Transplantation</i> , 2002, 17, 1649-1654. | 0.4 | 13 |
| 93 | Cefazolin dialytic clearance by high-efficiency and high-flux hemodialyzers. <i>American Journal of Kidney Diseases</i> , 2001, 37, 766-776. | 2.1 | 31 |
| 94 | Effect of cisapride on QT interval in patients with end-stage renal disease. <i>American Journal of Cardiology</i> , 2000, 86, 873-875. | 0.7 | 5 |
| 95 | Small and Middle Molecular Weight Solute Clearance in Nocturnal Intermittent Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , 1999, 19, 534-539. | 1.1 | 19 |
| 96 | Erythema Multiforme Secondary to Amoxicillin/Clavulanic Acid Exposure. <i>Annals of Pharmacotherapy</i> , 1999, 33, 109-110. | 0.9 | 3 |
| 97 | Low-Molecular Weight Protein Removal by High-Flux Dialyzers: Basic Mechanisms and Effect of Reprocessing. <i>Seminars in Dialysis</i> , 1999, 12, 349-354. | 0.7 | 8 |
| 98 | The Effects of Peracetic Acid-Hydrogen Peroxide Reprocessing on Dialyzer Solute and Water Permeability. <i>Pharmacotherapy</i> , 1999, 19, 1042-1049. | 1.2 | 11 |
| 99 | Effect of Gender on the Pharmacokinetics of Ofloxacin. <i>Pharmacotherapy</i> , 1999, 19, 442-446. | 1.2 | 19 |
| 100 | Dialyzer-dependent changes in solute and water permeability with bleach reprocessing. <i>American Journal of Kidney Diseases</i> , 1999, 33, 87-96. | 2.1 | 34 |
| 101 | Quantifying the Effect of Changes in the Hemodialysis Prescription on Effective Solute Removal with a Mathematical Model. <i>Journal of the American Society of Nephrology: JASN</i> , 1999, 10, 601-609. | 3.0 | 119 |
| 102 | Quantification of creatinine kinetic parameters in patients with acute renal failure. <i>Kidney International</i> , 1998, 54, 554-560. | 2.6 | 39 |
| 103 | Selection of narcotic analgesics for pain associated with pancreatitis. <i>American Journal of Health-System Pharmacy</i> , 1998, 55, 480-486. | 0.5 | 21 |
| 104 | Falsely elevated serum vancomycin concentrations in hemodialysis patients. <i>American Journal of Kidney Diseases</i> , 1996, 27, 67-74. | 2.1 | 32 |
| 105 | Uremic pruritus. <i>American Journal of Health-System Pharmacy</i> , 1996, 53, 2159-2170. | 0.5 | 28 |
| 106 | EFFICACY OF CONVECTIVE REMOVAL OF PLASMA MEDIATORS OF ENDOTOXIC SHOCK BY CONTINUOUS VENO-VENOUS HEMOFILTRATION. <i>Shock</i> , 1996, 5, 149-154. | 1.0 | 28 |
| 107 | Impact of the Nutritional Regimen on Protein Catabolism and Nitrogen Balance in Patients With Acute Renal Failure. <i>Journal of Parenteral and Enteral Nutrition</i> , 1996, 20, 56-62. | 1.3 | 103 |
| 108 | Mucositis management practices for hospitalized patients: National survey results. <i>Journal of Pain and Symptom Management</i> , 1995, 10, 510-520. | 0.6 | 49 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Comparison of Imipenem Pharmacokinetics in Patients With Acute or Chronic Renal Failure Treated With Continuous Hemofiltration. American Journal of Kidney Diseases, 1993, 21, 172-179. | 2.1 | 74 |
| 110 | Urea Kinetics During Continuous Hemofiltration. ASAIO Journal, 1992, 38, M664-M667. | 0.9 | 37 |
| 111 | Continuous Venovenous Hemofiltration: An Alternative to Continuous Arteriovenous Hemofiltration and Hemodiafiltration in Acute Renal Failure. American Journal of Kidney Diseases, 1991, 18, 451-458. | 2.1 | 82 |
| 112 | Vancomycin pharmacokinetics in acute renal failure: Preservation of nonrenal clearance. Clinical Pharmacology and Therapeutics, 1991, 50, 688-694. | 2.3 | 90 |